A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data
Abstract Vaccine efficacy is often assessed by counting disease cases in a clinical trial. A new quantitative framework proposed here (“PoDBAY,” Probability of Disease Bayesian Analysis), estimates vaccine efficacy (and confidence interval) using immune response biomarker data collected shortly afte...
Guardado en:
Autores principales: | Julie Dudášová, Regina Laube, Chandni Valiathan, Matthew C. Wiener, Ferdous Gheyas, Pavel Fišer, Justina Ivanauskaite, Frank Liu, Jeffrey R. Sachs |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/415ecc810f6745a2bf96f13f021d869a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
IMMUNOGENICITY OF ADJUVANT INFLUENZA VACCINE FOR PREGNANT WOMEN
por: M. P. Kostinov, et al.
Publicado: (2017) -
Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Waleed H. Mahallawi, et al.
Publicado: (2021) -
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
por: Kirill V. Kalnin, et al.
Publicado: (2021) -
Semiparametric maximum likelihood probability density estimation.
por: Frank Kwasniok
Publicado: (2021) -
Semiparametric maximum likelihood probability density estimation
por: Frank Kwasniok
Publicado: (2021)